Trial Designs for Targeted Therapies

descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2006 English Publisher:WileyJournal:Biometrical Journal, volume 48, pages 908-910 (issn: 0323-3847, eissn: 1521-4036,

Copyright policy )

Authors: Simon G, Thompson;

doi: 10.1002/bimj.200610293

pmid: 17240650

Trial Designs for Targeted Therapies

- Summary
- Subjects
- Metrics

Abstract

AbstractThis is a discussion of the paper ‘Making efficient use of patients in designing phase III trials investigating simultaneously a set of targeted therapies with different targets’ by Werner Vach and Rene dePont Christensen. (© 2006 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)

Related Organizations

Medical Research Council
United Kingdom
MRC Biostatistics Unit
United Kingdom

Keywords

Biometry, Patient Selection, Antineoplastic Agents, Drug Delivery Systems, Clinical Trials, Phase III as Topic, Research Design, Data Interpretation, Statistical, Neoplasms, Humans

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average